JP7524167B2 - Ｉｖ型コラーゲン疾患の処置のためのビフェニルスルホンアミド化合物 - Google Patents

Ｉｖ型コラーゲン疾患の処置のためのビフェニルスルホンアミド化合物 Download PDF

Info

Publication number
JP7524167B2
JP7524167B2 JP2021518888A JP2021518888A JP7524167B2 JP 7524167 B2 JP7524167 B2 JP 7524167B2 JP 2021518888 A JP2021518888 A JP 2021518888A JP 2021518888 A JP2021518888 A JP 2021518888A JP 7524167 B2 JP7524167 B2 JP 7524167B2
Authority
JP
Japan
Prior art keywords
subject
compound
pharma
pharmaceutical composition
alport
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021518888A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022514152A5 (cg-RX-API-DMAC10.html
JP2022514152A (ja
Inventor
ラドコ コマーズ，
セリア ジェンキンソン，
Original Assignee
トラビア セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68318947&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7524167(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by トラビア セラピューティクス， インコーポレイテッド filed Critical トラビア セラピューティクス， インコーポレイテッド
Publication of JP2022514152A publication Critical patent/JP2022514152A/ja
Publication of JP2022514152A5 publication Critical patent/JP2022514152A5/ja
Priority to JP2024114026A priority Critical patent/JP2024133735A/ja
Application granted granted Critical
Publication of JP7524167B2 publication Critical patent/JP7524167B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2021518888A 2018-10-04 2019-10-03 Ｉｖ型コラーゲン疾患の処置のためのビフェニルスルホンアミド化合物 Active JP7524167B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024114026A JP2024133735A (ja) 2018-10-04 2024-07-17 Ｉｖ型コラーゲン疾患の処置のためのビフェニルスルホンアミド化合物

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862741270P 2018-10-04 2018-10-04
US62/741,270 2018-10-04
US201962853904P 2019-05-29 2019-05-29
US62/853,904 2019-05-29
US201962894559P 2019-08-30 2019-08-30
US62/894,559 2019-08-30
PCT/US2019/054559 WO2020072814A1 (en) 2018-10-04 2019-10-03 Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024114026A Division JP2024133735A (ja) 2018-10-04 2024-07-17 Ｉｖ型コラーゲン疾患の処置のためのビフェニルスルホンアミド化合物

Publications (3)

Publication Number Publication Date
JP2022514152A JP2022514152A (ja) 2022-02-10
JP2022514152A5 JP2022514152A5 (cg-RX-API-DMAC10.html) 2022-10-06
JP7524167B2 true JP7524167B2 (ja) 2024-07-29

Family

ID=68318947

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021518888A Active JP7524167B2 (ja) 2018-10-04 2019-10-03 Ｉｖ型コラーゲン疾患の処置のためのビフェニルスルホンアミド化合物
JP2024114026A Pending JP2024133735A (ja) 2018-10-04 2024-07-17 Ｉｖ型コラーゲン疾患の処置のためのビフェニルスルホンアミド化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024114026A Pending JP2024133735A (ja) 2018-10-04 2024-07-17 Ｉｖ型コラーゲン疾患の処置のためのビフェニルスルホンアミド化合物

Country Status (13)

Country Link
US (1) US11207299B2 (cg-RX-API-DMAC10.html)
EP (1) EP3860594B1 (cg-RX-API-DMAC10.html)
JP (2) JP7524167B2 (cg-RX-API-DMAC10.html)
KR (1) KR102902972B1 (cg-RX-API-DMAC10.html)
CN (1) CN113286587A (cg-RX-API-DMAC10.html)
AU (1) AU2019354784B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021006132A2 (cg-RX-API-DMAC10.html)
CA (1) CA3114434A1 (cg-RX-API-DMAC10.html)
ES (1) ES3057657T3 (cg-RX-API-DMAC10.html)
IL (2) IL327175A (cg-RX-API-DMAC10.html)
MA (1) MA53817A (cg-RX-API-DMAC10.html)
MX (1) MX2021003606A (cg-RX-API-DMAC10.html)
WO (1) WO2020072814A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019530713A (ja) 2016-10-13 2019-10-24 レトロフィン， インコーポレイテッド 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物
WO2022246200A1 (en) * 2021-05-21 2022-11-24 Travere Therapeutics, Inc. Methods of treating kidney diseases or disorders
WO2022266370A1 (en) * 2021-06-17 2022-12-22 Aria Pharmaceuticals, Inc. Sparsentan for treating idiopathic pulmonary fibrosis
JP2025183466A (ja) * 2022-11-11 2025-12-17 株式会社アークメディスン 化合物、エンドセリンａ受容体拮抗剤、アンジオテンシンｉｉタイプ１受容体拮抗剤及び医薬組成物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018051298A1 (en) 2016-09-19 2018-03-22 Aten Porus Lifesciences Cyclodextrin based polymers, methods, compositions and applications thereof
WO2018071784A1 (en) 2016-10-13 2018-04-19 Retrophin, Inc. Biphenyl sulfonamide compounds for the treatment of kidney diseases or disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID26984A (id) 1998-07-06 2001-02-22 Bristol Myers Squibb Co Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda
US6638937B2 (en) 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
WO2001044239A2 (en) 1999-12-15 2001-06-21 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
WO2010114801A1 (en) 2009-03-31 2010-10-07 Ligand Pharmaceuticals Inc. Oral formulations of diphenylsulfonamide endothelin and angiotensin ii receptor agonists to treat elevated blood pressure and diabetic nephropathy
WO2010135350A2 (en) 2009-05-20 2010-11-25 Pharmacopeia, Llc Biphenyl intermediate compounds and methods for the preparation of a dual angiotensin ii and endothelin a receptor antagonist
US9719981B2 (en) 2012-08-17 2017-08-01 Father Flanagan's Boys' Home RAC1 inhibitors for the treatment of alport glomerular disease
US10744178B2 (en) * 2014-08-21 2020-08-18 Stealth Biotherapeutics Corp Methods and compositions for the prevention and treatment of disease
BR112021012226A2 (pt) 2018-12-21 2021-09-08 Travere Therapeutics, Inc. Composições de esparsentano amorfo

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018051298A1 (en) 2016-09-19 2018-03-22 Aten Porus Lifesciences Cyclodextrin based polymers, methods, compositions and applications thereof
WO2018071784A1 (en) 2016-10-13 2018-04-19 Retrophin, Inc. Biphenyl sulfonamide compounds for the treatment of kidney diseases or disorders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Hearing Research，2016年，Vol.341，p.100-108
Kidney International，2000年，Vol.57，p.2084-2092
Kidney International，2000年，Vol.58，p.1870-1875

Also Published As

Publication number Publication date
CA3114434A1 (en) 2020-04-09
MX2021003606A (es) 2021-08-16
ES3057657T3 (en) 2026-03-03
KR102902972B1 (ko) 2025-12-22
KR20210081338A (ko) 2021-07-01
AU2019354784A1 (en) 2021-04-15
US11207299B2 (en) 2021-12-28
IL281965B2 (en) 2026-08-01
AU2019354784B2 (en) 2025-07-10
EP3860594A1 (en) 2021-08-11
JP2022514152A (ja) 2022-02-10
MA53817A (fr) 2021-08-11
JP2024133735A (ja) 2024-10-02
IL281965A (en) 2021-05-31
US20200147050A1 (en) 2020-05-14
WO2020072814A1 (en) 2020-04-09
BR112021006132A2 (pt) 2021-07-20
EP3860594B1 (en) 2025-10-01
IL281965B1 (en) 2026-04-01
CN113286587A (zh) 2021-08-20
IL327175A (en) 2026-05-01

Similar Documents

Publication Publication Date Title
JP2024133735A (ja) Ｉｖ型コラーゲン疾患の処置のためのビフェニルスルホンアミド化合物
KR102528435B1 (ko) 신장 질환 또는 장애의 치료를 위한 비페닐 설폰아미드 화합물
MD3684344T2 (ro) Comprimate de deferipronă cu eliberare întârziată și metode de utilizare a acestora
EP3013327B1 (en) Pharmaceutical capsule composite formulation comprising tadalafil and tamsulosin
WO2022246200A1 (en) Methods of treating kidney diseases or disorders
KR20260021653A (ko) IgA 매개 질환의 치료 방법에 사용하기 위한 스파르센탄
WO2024073672A1 (en) Combination therapy with sparsentan and a sglt2 inhibitor for treating kidney diseases or disorders
EP1465607B1 (fr) Compositions pharmaceutiques a liberation modifiee
HK40059411A (en) Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases
HK40059411B (en) Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases
TW202122086A (zh) 嗜中性白血球彈性蛋白酶抑制劑在肺部疾病中之使用
AU2024343419A1 (en) Sparsentan for treating immunoglobulin a nephropathy (igan)
CA3071096A1 (en) Co-administration of minocycline and colistin to reduce acute kidney injury
KR20250024807A (ko) 플로로글루시놀 제제 및 사용 방법
CN111214465A (zh) 维拉帕米的抗衰老用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220928

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220928

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230926

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240312

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240618

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240717

R150 Certificate of patent or registration of utility model

Ref document number: 7524167

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150